



Please place a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|-------------------|
| Substitute for form 1449A/PTO | | | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Application Number | 10/519,594 |
| | | | | Filing Date | December 28, 2004 |
| | | | | First Named Inventor | David Cavalla |
| | | | | Group Art Unit | Not yet assigned |
| | | | | Examiner Name | Not yet assigned |
| | | | | Attorney Docket Number | GJE-6758 |
| Sheet | 1 | of | 1 | | |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|----------------------|--------------------------------------|---|--|---|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number | Kind Code ² (if known) | | | |
| LS | U1 | 6,284,770 | | Mangel et al. | 09-04-2001 | |
| LS | U2 | 4,695,568 | | Ninomiya et al. | 09-22-1987 | |
| | U3 | | | | | |
| | U4 | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----------------------|-------------------------|---------------------|--------------------------------------|---|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ³ |
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| LS | F1 | CA | 2431074 | | Merck Patent GMBH | 06-27-2002 | | |
| LS | F2 | DE | 100 63 223 | | GMBH | 06-20-2002 | Abstract | |
| | F3 | | | | | | | |
| | F4 | | | | | | | |
| | F5 | | | | | | | |
| | F7 | | | | | | | |
| | F8 | | | | | | | |

| OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS | | | | | | | |
|---|-----------------------|--|--|--|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | | | T ² |
| LS | R1 | CROWELL M. D., "The Role of Serotonin in the Pathophysiology of Irritable Bowel Syndrome," <i>American Journal of Managed Care</i> , 2001, 7:S252-S260. | | | | | |
| LS | R2 | EGUCHI J. et al., "The Anxiolytic-like Effect of MCI-225, a Selective NA Reuptake Inhibitor With 5-HT3 Receptor Antagonism," <i>Pharmacology, Biochemistry and Behavior</i> , 2000, 68:677-683. | | | | | |
| | R3 | | | | | | |

| | | | |
|--------------------|-----------------|-----------------|------------|
| Examiner Signature | /Layla Soroush/ | Date Considered | 07/17/2006 |
|--------------------|-----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.